Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
SINGAPORE, Jul 24, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc.
Global BioLife's Director of Scientific Initiatives Mr Daryl L.Thompson was invited to present the new formula to health ambassadors from around the world at Harvard Medical School's Global Health Catalyst Summit, an annual event that focuses on initiatives to eliminate global health disparities.
Clinical trial results show that Laetose is a new sugar product that reduces its negative impact on the body. It is a healthier sweetener that is identical to regular sugar in taste, texture and shelf life, but a naturally modified table sugar which carries 30% fewer calories and a glycemic index score of 53 as compared to a score of 100 in glucose.
"You can think of Laetose as Sugar 2.0. It is more than a low-calorie sugar, but rather a solution to sugar itself in that it was specifically formulated to fight disease," said Mr Thompson. "We've developed a formula that uses sugar the way nature intended. Laetose tastes and performs exactly like sugar as a food ingredient but it is better accepted by the body."
Mr Thompson announced the completion of human trials on Laetose, conducted at one of the foremost laboratories in the world to measure glycemic index, with additional independent testing conducted at Charles River Laboratories showing Laetose halts stimulation of lipopolysaccharide inflammation which leads to Metabolic Endotoxemia, the root of metabolic-driven disease.
Global BioLife has partnered with Quality Candy Company LLC to form a joint venture, Sweet Sense Inc., to produce and market Laetose. Sweet Sense refined the formula at its production facility and created a scalable manufacturing process for Laetose.
"Clinical trials are complete, patents have been filed and the product is ready for full-scale production," said Mr Thompson. Sweet Sense is looking to licence Laetose and is sourcing for companies with the ability to introduce Laetose into multiple food products around the world.
Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, there is no certainty or assurance that Laetose will be licensed or come close to monetisation. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about actions they should take.
About Singapore eDevelopment Ltd Incorporated on 9 September 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email: contact@sed.com.sg.
About Global BioLife Inc. Global BioLife Inc. (GBLI) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned subsidiary of Singapore BioMedical Pte. Ltd., itself a wholly-owned subsidiary of Singapore eDevelopment Ltd, a company listed on the SGX. Remaining shares are held by Global Research and Discovery Group Scientific LLC (GRDGS) at 20% and ASX-listed Holista CollTech Limited at 10%.
GBLI strives to leverage its scientific know-how and intellectual property to provide solutions to problems that have been plaguing the biomedical field for decades. Tapping the scientific expertise of GRDGS and Holista, GBLI pledges a concerted effort in R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with partners to develop second generation, DEET alternative mosquito defense technologies to protect against diseases such as Zika, Dengue, West Nile Virus and Malaria. For more information, please visit: http://www.globalbiolife.com.
Source: Alset International Ltd Sectors: Daily Finance, Food & Beverage, BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
| New circuit challenge for TOYOTA GAZOO Racing Apr 15, 2024 17:21 JST
| TOYOTA GAZOO Racing back on asphalt for Croatian challenge Apr 12, 2024 19:36 JST
| Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project Apr 12, 2024 14:39 JST
| MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors Apr 11, 2024 18:08 JST
| Mitsubishi Shipbuilding Acquires Approval in Principle (AiP) from Classification Society ClassNK for Ammonia Fuel Supply System (AFSS) Apr 11, 2024 17:50 JST
| DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission Apr 11, 2024 15:10 JST
| Mitsubishi Corporation Announces Completion of Capital Raise by Nexamp Apr 11, 2024 13:07 JST
| Mitsubishi Shipbuilding Receives Order for Ammonia Fuel Supply System for Ammonia-Powered Marine Engine Apr 10, 2024 16:55 JST
| Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 Apr 10, 2024 13:36 JST
|
More Latest Release >>
|